XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

Inclusion Criteria:

* Measurable disease at baseline per RECIST v1.1
* ECOG performance status of 0 or 1
* Adequate organ function
* Metastatic NSCLC:

  * Must have histologically confirmed metastatic NSCLC.
  * Tumor must have been assessed for EGFR and ALK per local standard of practice; patients with these driver mutations are excluded.
  * Patients with tumors known to have the following alterations are excluded: ROS1, RET, MET, HER-2, NTRK 1/2/3.
  * Patients must have previously derived clinical benefit from a PD-1/PD-L1 inhibitor or PD-1/PDL-1 bispecific without progression for at least 6 months.

Exclusion Criteria:

* Prior treatment with IL-2
* History of significant pulmonary disease
* History of clinically significant cardiovascular disease
* Active CNS metastases
* Pregnant or breastfeeding

In Phase 1, participants with select additional solid tumor types may be enrolled.